180 related articles for article (PubMed ID: 19629978)
1. Evaluating the role of zinc in the occurrence of fibrosis of the skin: a preclinical study.
Pietsch H; Pering C; Lengsfeld P; Walter J; Steger-Hartmann T; Golfier S; Frenzel T; Hütter J; Weinmann HJ; Sieber MA
J Magn Reson Imaging; 2009 Aug; 30(2):374-83. PubMed ID: 19629978
[TBL] [Abstract][Full Text] [Related]
2. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media.
Sieber MA; Pietsch H; Walter J; Haider W; Frenzel T; Weinmann HJ
Invest Radiol; 2008 Jan; 43(1):65-75. PubMed ID: 18097279
[TBL] [Abstract][Full Text] [Related]
3. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents.
Pietsch H; Lengsfeld P; Steger-Hartmann T; Löwe A; Frenzel T; Hütter J; Sieber MA
Invest Radiol; 2009 Apr; 44(4):226-33. PubMed ID: 19252439
[TBL] [Abstract][Full Text] [Related]
4. Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand.
Sieber MA; Lengsfeld P; Walter J; Schirmer H; Frenzel T; Siegmund F; Weinmann HJ; Pietsch H
J Magn Reson Imaging; 2008 May; 27(5):955-62. PubMed ID: 18425843
[TBL] [Abstract][Full Text] [Related]
5. Effects of gadolinium contrast agents in naïve and nephrectomized rats: relevance to nephrogenic systemic fibrosis.
Grant D; Johnsen H; Juelsrud A; Løvhaug D
Acta Radiol; 2009 Mar; 50(2):156-69. PubMed ID: 19160079
[TBL] [Abstract][Full Text] [Related]
6. The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis - a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide.
Steger-Hartmann T; Raschke M; Riefke B; Pietsch H; Sieber MA; Walter J
Exp Toxicol Pathol; 2009 Nov; 61(6):537-52. PubMed ID: 19131226
[TBL] [Abstract][Full Text] [Related]
7. Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure.
Fretellier N; Bouzian N; Parmentier N; Bruneval P; Jestin G; Factor C; Mandet C; Daubiné F; Massicot F; Laprévote O; Hollenbeck C; Port M; Idée JM; Corot C
Toxicol Sci; 2013 Jan; 131(1):259-70. PubMed ID: 22977165
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of lanthanoids as X-ray contrast agents.
Pietsch H; Jost G; Frenzel T; Raschke M; Walter J; Schirmer H; Hütter J; Sieber MA
Eur J Radiol; 2011 Nov; 80(2):349-56. PubMed ID: 20006455
[TBL] [Abstract][Full Text] [Related]
9. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis.
Abraham JL; Thakral C; Skov L; Rossen K; Marckmann P
Br J Dermatol; 2008 Feb; 158(2):273-80. PubMed ID: 18067485
[TBL] [Abstract][Full Text] [Related]
10. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
Lohrke J; Frisk AL; Frenzel T; Schöckel L; Rosenbruch M; Jost G; Lenhard DC; Sieber MA; Nischwitz V; Küppers A; Pietsch H
Invest Radiol; 2017 Jun; 52(6):324-333. PubMed ID: 28323657
[TBL] [Abstract][Full Text] [Related]
11. Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron.
Hope TA; High WA; Leboit PE; Chaopathomkul B; Rogut VS; Herfkens RJ; Brasch RC
Radiology; 2009 Nov; 253(2):390-8. PubMed ID: 19789237
[TBL] [Abstract][Full Text] [Related]
12. The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats.
Pietsch H; Raschke M; Ellinger-Ziegelbauer H; Jost G; Walter J; Frenzel T; Lenhard D; Hütter J; Sieber MA
Invest Radiol; 2011 Jan; 46(1):48-56. PubMed ID: 20938346
[TBL] [Abstract][Full Text] [Related]
13. [Nephrogenic systemic fibrosis--new clinical entity].
Prvulović M
Med Pregl; 2008; 61(9-10):439-41. PubMed ID: 19203058
[TBL] [Abstract][Full Text] [Related]
14. A review of preclinical safety data for magnevist (gadopentetate dimeglumine) in the context of nephrogenic systemic fibrosis.
Steger-Hartmann T; Hofmeister R; Ernst R; Pietsch H; Sieber MA; Walter J
Invest Radiol; 2010 Sep; 45(9):520-8. PubMed ID: 20644486
[TBL] [Abstract][Full Text] [Related]
15. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.
Broome DR
Eur J Radiol; 2008 May; 66(2):230-4. PubMed ID: 18372138
[TBL] [Abstract][Full Text] [Related]
16. Gadolinium-based contrast agents and NSF: evidence from animal experience.
Sieber MA; Steger-Hartmann T; Lengsfeld P; Pietsch H
J Magn Reson Imaging; 2009 Dec; 30(6):1268-76. PubMed ID: 19938039
[TBL] [Abstract][Full Text] [Related]
17. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions.
Sieber MA; Lengsfeld P; Frenzel T; Golfier S; Schmitt-Willich H; Siegmund F; Walter J; Weinmann HJ; Pietsch H
Eur Radiol; 2008 Oct; 18(10):2164-73. PubMed ID: 18545998
[TBL] [Abstract][Full Text] [Related]
18. NSF after Gadovist exposure: a case report and hypothesis of NSF development.
Wollanka H; Weidenmaier W; Giersig C
Nephrol Dial Transplant; 2009 Dec; 24(12):3882-4. PubMed ID: 19767635
[TBL] [Abstract][Full Text] [Related]
19. Skin gadolinium following use of MR contrast agents in a rat model of nephrogenic systemic fibrosis.
Haylor J; Schroeder J; Wagner B; Nutter F; Jestin G; Idée JM; Morcos S
Radiology; 2012 Apr; 263(1):107-16. PubMed ID: 22344402
[TBL] [Abstract][Full Text] [Related]
20. Influence of excess ligand on Nephrogenic Systemic Fibrosis associated with nonionic, linear gadolinium-based contrast agents.
Semelka RC; Prybylski JP; Ramalho M
Magn Reson Imaging; 2019 May; 58():174-178. PubMed ID: 30471330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
